BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30322880)

  • 1. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J
    Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
    Azad TD; Jin MC; Bernhardt LJ; Bettegowda C
    Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
    Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
    Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in H3K27M diffuse midline glioma.
    Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
    Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
    Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
    J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
    Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas.
    On J; Natsumeda M; Watanabe J; Saito S; Kanemaru Y; Abe H; Tsukamoto Y; Okada M; Oishi M; Yoshimura J; Kakita A; Fujii Y
    Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33918936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA.
    Pan C; Diplas BH; Chen X; Wu Y; Xiao X; Jiang L; Geng Y; Xu C; Sun Y; Zhang P; Wu W; Wang Y; Wu Z; Zhang J; Jiao Y; Yan H; Zhang L
    Acta Neuropathol; 2019 Feb; 137(2):297-306. PubMed ID: 30460397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
    BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
    Wierzbicki K; Ravi K; Franson A; Bruzek A; Cantor E; Harris M; Homan MJ; Marini BL; Kawakibi AR; Ravindran R; Teodoro R; Yadav VN; Koschmann C
    Curr Oncol Rep; 2020 Feb; 22(2):19. PubMed ID: 32030483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
    Kojic M; Maybury MK; Waddell N; Koufariotis LT; Addala V; Millar A; Wood S; Pearson JV; Hansford JR; Hassall T; Wainwright BJ
    Neuro Oncol; 2023 Aug; 25(8):1507-1517. PubMed ID: 36757207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic?
    Simonelli M; Dipasquale A; Orzan F; Lorenzi E; Persico P; Navarria P; Pessina F; Nibali MC; Bello L; Santoro A; Boccaccio C
    Crit Rev Oncol Hematol; 2020 Feb; 146():102879. PubMed ID: 32005411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors].
    Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R
    No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 19. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.